Internal Medicine · Folsom, CA
NPI
1902878978
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1600 Creekside Dr Ste 2700
Folsom, CA, 95630
Phone (530) 677-0700
Groups this clinician bills Medicare through
Medicare paid, 2024
$108K
10,073 services
Medicare patients, 2024
356
Average age 73
Drug cost, 2024
$4.8M
4,692 prescriptions
Company payments, 2025
$49K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaiwant K Rangi was code 99214 (office e&m - established), 716 times for 317 patients. In total Jaiwant K Rangi billed 10,073 services in 18 codes, and Medicare paid $108K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-11-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 716 | 317 | $89.27 | $64K |
| 95251 Test - Miscellaneous | Office | 469 | 179 | $24.30 | $11K |
| 99443 Telephone Services | Office | 152 | 118 | $88.60 | $13K |
| 96372 Injection Administration | Office | 130 | 22 | $10.88 | $1,415 |
| 99215 Office E&M - Established | Office | 51 | 49 | $132.96 | $6,781 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 50 | 15 | $1.00 | $50.02 |
| 99205 Office E&M - New | Office | 41 | 41 | $159.58 | $6,543 |
| 99213 Office E&M - Established | Office | 21 | 15 | $66.28 | $1,392 |
| 99442 Telephone Services | Office | 12 | 11 | $69.54 | $834 |
By year: 2022 $137K for 4,158 services; 2023 $111K for 6,197 services; 2024 $108K for 10,073 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jaiwant K Rangi prescribed most often to Medicare patients was Ozempic (Semaglutide), with 625 prescriptions and refills. In total Jaiwant K Rangi wrote 4,692 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 625 | 971 | 137 | $914K |
| Levothyroxine Sodium Generic | 307 | 822 | 94 | $5,302 |
| Mounjaro Tirzepatide | 300 | 437 | 54 | $456K |
| Pioglitazone Hcl Generic | 231 | 589 | 67 | $3,163 |
| Jardiance Empagliflozin | 205 | 503 | 59 | $291K |
| Metformin Hcl Generic | 201 | 545 | 59 | $2,130 |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 128 | 310 | 40 | $167K |
| Trulicity Dulaglutide | 128 | 191 | 31 | $180K |
| Tresiba Flextouch U-200 Insulin Degludec | 124 | 282 | 34 | $165K |
| Synthroid Levothyroxine Sodium | 117 | 329 | 38 | $12K |
| Afrezza Insulin Regular, Human | 105 | 113 | 15 | $168K |
| Tresiba Flextouch U-100 Insulin Degludec | 105 | 280 | 38 | $63K |
| Atorvastatin Calcium Generic | 96 | 282 | 32 | $998 |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 95 | 266 | 36 | $60K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 90 | 250 | 44 | $8,326 |
Brand drugs: 2,840 claims; generic drugs: 1,459 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaiwant K Rangi $49K ($49K in general payments such as food, travel and fees) from 16 companies. The largest payer was Novo Nordisk Inc with $24K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 29 | $24K |
| Abbott Laboratories ABT | 30 | $11K |
| Sanofi-Aventis U.S. LLC SNY | 14 | $10K |
| Mannkind Corporation MNKD | 23 | $1,520 |
| Medtronic, Inc. MDT | 23 | $867 |
| Sequel Med Tech, LLC | 17 | $633 |
| Amgen Inc. AMGN | 19 | $256 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 17 | $176 |
| Xeris Pharmaceuticals, Inc. | 4 | $83.76 |
| IBSA Pharma Inc. | 2 | $39.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.